The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description

• Autor(a) principal: Hoexter,Marcelo Queiroz
• Data de Publicação: 2009
• Outros Autores: Shavitt,Roseli Gedanke, D'Alcante,Carina Chaubet, Cecconi,Janaina Philippi, Diniz,Juliana Belo, Belotto-Silva,Cristina, Hounie,Ana Gabriela, Borcato,Sonia, Moraes,Ivanil, Joaquim,Marines Alves, Cappi,Carolina, Sampaio,Aline Santos, Mathis,Maria Alice de, Batistuzzo,Marcelo Camargo, Lopes,Antonio Carlos, Rosa,Ana Carolina Ferreira, Muniz,Renan Kawano, Marques,Andrea Horvath, Santos,Luciana Cristina, Taub,Anita, Duran,Fábio Luís de Souza, Dougherty,Darin Dean, Busatto,Geraldo Filho, Bressan,Rodrigo Affonseca, Miguel,Euripedes Constantino
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462009000400011
• topic: Obsessive-compulsive disorder; Genetics; Cognition; Imaging; Treatment outcome

OBJECTIVE: To describe a protocol that was based on an integrative neurobiological model of scientific investigation to better understand the pathophysiology of obsessive-compulsive disorder and to present the clinical and demographic characteristics of the sample. METHOD: A standardized research protocol that combines different methods of investigation (genetics, neuropsychology, morphometric magnetic resonance imaging and molecular neuroimaging of the dopamine transporter) obtained before and after treatment of drug-naïve adult obsessive-compulsive disorder patients submitted to a sequentially allocated 12-week clinical trial with a selective serotonin reuptake inhibitor (fluoxetine) and group cognitive-behavioral therapy. RESULTS: Fifty-two treatment-naïve obsessive-compulsive disorder patients entered the clinical trial (27 received fluoxetine and 25 received group cognitive-behavioral therapy). At baseline, 47 blood samples for genetic studies, 50 neuropsychological evaluations, 50 morphometrical magnetic resonance images and 48 TRODAT-1 single-photon emission computed tomography (SPECT) exams were obtained. After 12 weeks, 38 patients completed the protocol (fluoxetine = 20 and GCBT = 18). Thirty-eight neuropsychological evaluations, 31 morphometrical magnetic resonance images and 34 TRODAT-1 SPECT exams were obtained post-treatment. Forty-one healthy controls matched for age, gender, socioeconomic status, level of education and laterality were submitted to the same research procedures at baseline. CONCLUSION: The comprehensive treatment response protocol applied in this project allowing integration on genetic, neuropsychological, morphometrical and molecular imaging of the dopamine transporter data in drug-naïve patients has the potential to generate important original information on the neurobiology of obsessive-compulsive disorder, and at the same time be clinically meaningful.